Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MBX Biosciences, Inc. (MBX)

MBX Biosciences Q3 net loss widens to $62.4 million from $21.6 million a year earlier

Negative Impact 3 of 5 earnings

MBX Biosciences reported a third-quarter 2026 net loss of $62.4 million, up from $21.6 million a year earlier, as research and development and general and administrative expenses both rose sharply. The company said cash, cash equivalents and marketable securities were $481.6 million at September 30, 2026, which it expects to fund operations into 2029, and the filing notes that $20.8 million of the G&A increase was stock-based compensation tied to modified awards for its former chief executive officer.

Key points

  • Net loss was $62.4 million, or $1.29 per share, for the quarter ended September 30, 2026, versus $21.6 million, or $0.63 per share, a year earlier.
  • R&D expenses rose to $32.0 million from $19.3 million, driven in part by start-up costs for the canvuparatide Phase 3 trial, which started in the third quarter.
  • G&A expenses rose to $34.3 million from $4.7 million, including $20.8 million of stock-based compensation tied to modified awards for the former CEO.
  • Cash, cash equivalents and marketable securities were $481.6 million, including $97.6 million net proceeds from at-the-market stock sales.

The filing

CompanyMBX Biosciences, Inc. (MBX)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:05 PM ET
Accession number0001193125-26-453553

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 5:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.